Cadila Pharma to launch cancer drug under brand name Bevaro in India
Bevasizumab is used in the treatment of multiple cancers which are common in India like Ovarian Cancer, Glioblastoma Multiforme, Colorectal Cancer, Breast Cancer, Lung Cancer, Cervical Cancer, Kidney Cancer
Ahmedabad: Ahmedabad-based Cadila Pharmaceuticals Limited has announced the launch of Bevasizumab biosimilar for the domestic market.
Bevasizumab biosimilar is a humanized monoclonal antibody, recommended in multiple indications and will be launched under the brand name Bevaro™.
Bevasizumab is used in the treatment of multiple cancers which are common in India like Ovarian Cancer, Glioblastoma Multiforme (a type of Brain cancer), Colorectal Cancer, Breast Cancer, Lung Cancer, Cervical Cancer and Kidney Cancer.
In a commitment to further strengthen the oncology portfolio Cadila's Bevaro™ will be made available in a single-dose vial of two strengths, 100 mg and 400mg.
Biosimilar products like Bevaro™ are safe and more efficacious compared to conventional treatment medicines. Cadila plans to launch multiple biosimilar products this year for the Indian Market.
Cadila Pharmaceuticals Ltd. has recently concluded and cleared USFDA inspection successfully in February 2020.
Cadila Pharmaceuticals is a multinational research-based pharmaceutical group in India with more than 6 decades of experience.
